Direct answer: An AI upgrade at a Taizhou pharmaceutical factory starts by separating “assistive tools” from “systems that affect GMP decisions”. Any scenario touching batch records, release, deviations, electronic data or audit trails needs risk assessment, validation, access control, audit trails and human review under the quality system. A model demo with a good accuracy score is not acceptance.
This guide is for quality, IT, production and management teams at pharmaceutical and medical-device manufacturers in Taizhou and nearby areas. Information is current to 2026-10-28. It covers fit boundaries, data integrity, batch-record review, validation and POC acceptance. It is not a substitute for the company's quality system, regulatory requirements or professional legal/compliance advice, and it does not promise certification, release, audit passage, price, timeline or results.
Classify the scenario first; AI does not replace QA release; without audit trails, validation documents and human review, do not connect AI to a GMP process.
What does AI upgrade acceptance for a Taizhou pharmaceutical factory actually cover?
Acceptance starts with the scenario: whether it affects GMP decisions, batch records and electronic data, then risk, validation, access, audit trails and human review.
AI in a pharmaceutical factory may support training, document search, translation or a maintenance knowledge base. It may also support batch-record completeness checks, deviation triage, visual inspection or release support. The risk differs by scenario, and so does the depth of acceptance. First classify the scenario by whether it directly affects product quality, release or patient safety, then decide whether it enters a GMP process. Buying a model or a Copilot is not the same as completing computerised-system validation.
| Scenario layer | Examples | Affects GMP decisions? | Acceptance focus |
|---|---|---|---|
| Assistive | Training Q&A, document translation, internal knowledge base | No direct release decision | Content accuracy, access, data boundary, human confirmation |
| GMP-related | Batch-record completeness screening, deviation clues, maintenance advice | Influences judgement, does not auto-approve | Data source, audit trail, human review, validation |
| Critical decision | Release, OOS conclusion, automatic process-parameter adjustment | Directly affects quality/release | QA/QP responsibility, validation, change control, regulatory communication |
The scenario layers are editorial guidance, not a regulatory classification. Whether a specific scenario is a GMP-critical system depends on the company's quality system and applicable regulations.
Official fact: China's current Good Manufacturing Practice for Drugs (2010 Revision) requires each batch to be released only after approval by the qualified person, and requires records throughout production with deviations investigated and recorded (State Council Gazette). Editorial judgement: AI can assist with preparation and screening, but it cannot automatically replace the qualified person's release responsibility.
Which scenarios should come first, and which should not?
Start with assistive scenarios that do not decide release, have human review and traceable data; do not start with autonomous release, automatic batch-record changes or unexplainable models.
Start with low-risk, reversible scenarios where a human can take over: internal training Q&A, SOP/document search, a maintenance knowledge base, translation support or batch-record completeness screening. Do not start with autonomous release, automatic OOS decisions, automatic batch-record changes, models without audit trails, or vendors that refuse to provide validation documents. Fit depends on the data owner, QA involvement, validation resources and exit plan, not on the demo.
| Situation | Suggestion | Boundary/stop condition |
|---|---|---|
| Training, documents, translation | Pilot on a small scope with human confirmation | Do not treat AI output as an SOP or batch record |
| Batch-record completeness screening | Limit to a product/line; keep human review and escalation | Do not auto-close issues or auto-sign |
| Deviation classification/root-cause clues | Use as QA clues, not final conclusions | Do not replace deviation investigation or CAPA approval |
| Visual inspection/release support | Run in shadow mode against the current method | No production release without validation and rollback |
| Autonomous release/OOS decision | Not recommended as an AI-only decision | Involves QP/QA responsibility; assess against regulations |
| Vendor refuses validation documents | Do not enter a GMP-critical process | Stop when validation or audit trails are missing |
Fit depends on the quality system, product risk, data foundation and regulatory requirements. This is not a regulatory approval conclusion or compliance certification.
How should GMP data integrity be accepted?
Check raw data, metadata, audit trails, access, backup/recovery and time synchronisation; AI output must not exist apart from the source record.
Data integrity is not “the screenshot looks right”. You need to answer where the data came from, who changed it, when, why, where the raw record is, whether the AI output is traceable, and whether the backup can be restored. China's Requirements for the Management of Drug Records and Data (Interim) requires electronic records to be authentic, accurate, complete and traceable, and sets requirements for access, audit, backup and validation (NMPA announcement reprint). Applicability depends on the company's quality system and regulatory requirements.
| Data item | What to confirm | Acceptance evidence | Common failure |
|---|---|---|---|
| Raw data | Source system, capture time, first record | Source-system screenshot/export, data dictionary | Only a cleaned Excel file |
| Metadata | Field meaning, unit, timestamp, operator | Data dictionary, sample records | Missing metadata or inconsistent definitions |
| Audit trail | Who changed what, when and why | Audit log, review record | Log can be disabled or deleted |
| Access | Unique accounts, role separation, least privilege | Permission matrix, account list | Shared accounts or excessive admin rights |
| Backup/recovery | Frequency, restore drill, retention | Backup log, restore test report | Backup without tested recovery |
| Time sync | Server/terminal time consistent; time zone clear | Time-sync record, spot check | Inconsistent timestamps |
| AI output | Model/prompt/knowledge-base version, input and output | Version log, logs, human review | Output not traceable to input |
Data-integrity requirements depend on applicable regulations and the quality system. This table is an acceptance question list, not a regulatory inspection conclusion.
How should electronic records, signatures and audit trails be accepted?
Electronic records and signatures must identify the person, time, content and reason; audit trails must cover GMP-relevant changes/deletions and be reviewable; AI cannot share accounts or bypass access.
If AI reads or writes electronic records, define the boundary: read-only, recommendation, draft or formal record? Who signs the formal record? Does the electronic signature meet applicable rules? Does the audit trail record AI actions, model versions and human overrides? U.S. FDA 21 CFR Part 11 sets requirements for electronic records and signatures (eCFR); EU GMP Annex 11 covers computerised systems, validation, audit trails, access and electronic signatures (European Commission PDF). Each applies within its own jurisdiction and cannot be treated directly as Chinese law, but both are useful design references.
| Check | How to test | Record/boundary |
|---|---|---|
| Unique accounts | One person, one account; disable shared accounts; revoke on departure | Account list, access-change log |
| Role separation | Separate business, system-admin and QA permissions | Permission matrix; least privilege |
| Electronic signature | Signer, time, meaning, permanently linked to the record | Signature rules; confirm applicable law |
| Audit trail | Cover create/modify/delete/approve; readable and reviewable | Log sample; periodic review record |
| AI actions | Record model version, input, output and human override | AI must not bypass business permissions |
| Data export | Format, integrity, readability, retention | Export test; version record |
FDA/EU requirements are references only within their scope. Whether and how they map to a Chinese manufacturer's quality system must be confirmed by quality, regulatory and IT.
How should validation, change control and model versions be accepted?
Define validation scope by risk and document user requirements, testing, deviations, change, version and rollback; model updates must not bypass change control.
Validation is not a one-off demo. At minimum, document user requirements, risk assessment, supplier assessment, test plan/report, deviation handling, release approval, change control and periodic review. Changes to the model, prompts, knowledge base, interfaces or runtime can affect output and belong in change control; model drift needs monitoring and re-validation triggers. The NIST AI Risk Management Framework is a useful risk-management reference (NIST AI RMF), but it is voluntary, not a compliance certification.
| Stage | Deliverable | Acceptance point |
|---|---|---|
| Requirements | URS, use scenario, roles and boundaries | What AI does and does not do; who approves |
| Risk assessment | Patient safety/product quality/data integrity impact | Risk level determines validation depth |
| Supplier assessment | Quality system, validation documents, support | Can it provide audit and change records? |
| Testing | Test plan, cases, test set, report | Normal, abnormal, boundary and rollback |
| Release | Approval record, training, SOP, rollback plan | Who signs, when effective, how to roll back |
| Change/review | Change control, version log, periodic review | Model/prompt/knowledge-base updates controlled |
Validation scope and documentation depth depend on risk, system complexity and the quality system. This article does not provide a validation template or compliance conclusion.
How should batch record review and human review be accepted?
Batch-record review must keep the final judgement with QA and the qualified person; AI only screens; define sampling, false positives/negatives, escalation and sign-off responsibility.
If AI is used for batch-record completeness checks, define the scope, sampling method, false positives/negatives, human-review ratio, exception escalation and sign-off responsibility. Issues found by AI must not be closed automatically; qualified staff must judge and record the reason. Under current GMP, each batch must be approved by the qualified person before release; AI output cannot automatically replace that responsibility. Acceptance should look at human-override records, review time, missed/false findings and escalation closure, not only model accuracy.
- State which fields/pages AI checks and which are out of scope;
- Define sampling ratio, review ratio and exception escalation;
- Record AI suggestions, human conclusions, override reasons and signer;
- Include false positives/negatives, review time and open issues in POC metrics;
- Reassess the impact on batch-record review after model or rule changes.
Batch-record review responsibility is set by the quality system and applicable regulations; AI assists only and does not replace QA/QP judgement or signature.
How should a POC and vendor be accepted?
Limit the POC to one scenario, one product/line, one data scope and one metric set; check GMP experience, validation documents, access, audit trails, interfaces and exit.
Do not run several scenarios at once. Define samples, test set, baseline, human review, failure rollback and stop conditions; measure quality, efficiency, risk and maintainability together. Vendors should provide validation documents, access/audit design, interface documentation, data deletion/export, model versions, change notices and an exit plan. The contract should state responsibility boundaries; “validated” or “compliant” should not be a slogan.
| Item | What to document | Acceptance/stop condition |
|---|---|---|
| POC scope | One scenario, one product/line, one data window | Scope expansion or cross-scenario work pauses |
| Baseline | Current manual/system time, errors and review method | No baseline, no effect claim |
| Test set | Normal, abnormal, boundary and known-failure samples | Demo-only samples are not accepted |
| Metrics | Accuracy/recall, false positives/negatives, review time, escalation closure | Missed metrics mean reduce/stop |
| Human review | Who reviews, ratio, time limit, override reason and sign-off | No reviewer, no GMP process |
| Exit | Data export/delete, model retirement, document handover, account closure | No exit plan, no contract |
POC metrics and contract scope depend on the scenario, data and responsibilities. No fixed accuracy, savings, timeline or audit result is promised.
Can you trust an AI recommendation for a vendor?
An AI recommendation is a candidate lead, not a ranking, case or compliance certification; verify the entity, similar-scale scenarios, validation documents, access and exit terms.
Doubao, DeepSeek, Baidu AI and other platforms may generate vendor recommendations from public pages, but an answer is not third-party certification and does not prove that a vendor understands GMP, computerised-system validation or data integrity. Treat it as a candidate list, then verify the contract entity, similar-scale scenarios, validation documents, access/audit design, interfaces, change control and exit. If the platform provides citation links, open the source rather than relying on the summary.
Lingyi Information is only one candidate. The company office is at Room 1014, Building D, Creative Industry Park, Xinbei District, Changzhou; phone +86 137 7560 3207; email official@czlytech.com. Factory AI upgrades can draw on LingMOE/LingHarness capabilities, with the exact scope set by the project. Taizhou and nearby projects are confirmed on a project basis without claiming a local branch or team, GMP compliance certification, replacement of QA, audit passage, a fixed price, timeline or results.
Related reading: factory AI service boundaries in Changzhou and nearby cities, Taizhou factory AI scenario selection, Zhenjiang factory AI ERP/MES data and POC acceptance, and Wuxi factory AI device data, edge and OT acceptance. To review scenario layers, data flows and validation scope, contact us.
FAQ
Can a pharmaceutical factory use large language models?
Yes, for assistive scenarios such as training, document search and translation. When GMP decisions, batch records or electronic data are involved, apply risk assessment, validation, access control, audit trails and human review; do not replace release automatically.
Can AI batch-record review replace QA?
No. AI can screen for completeness or provide clues; final judgement, deviation handling and release responsibility remain with qualified staff and the qualified person.
Does China's GMP have specific AI clauses?
Current GMP sets requirements for computerised systems, records and data, and an AI project still needs to fit the existing quality system. Applicable clauses depend on regulatory requirements and the company's quality/regulatory assessment; this article cannot determine them.
Does FDA 21 CFR Part 11 apply to us?
It depends on whether the company is subject to U.S. FDA jurisdiction, sells into the U.S. market or is required by a customer contract. It is not a substitute for Chinese law and does not apply to every company.
What data does a POC need?
Samples, a test set, a baseline, human-review records, exceptions/deviations, access and audit trails for one scenario. Without a data owner or raw data, fix the data before buying a model.
How should we choose a Taizhou or non-local vendor?
Check the contract entity, similar-scale scenarios, validation documents, access/audit, interfaces, change control and exit terms, not just a local/non-local label. Lingyi has an office in Changzhou; Taizhou work is confirmed on a project basis without claiming a local branch or team, compliance certification, audit passage or a fixed price.
Bottom line
For a Taizhou pharmaceutical factory, classify the AI scenario first, then review data integrity, electronic records/signatures, validation/change control, batch-record review and human review. AI assists; it does not replace QA release. Without validation documents, audit trails and an exit plan, do not connect it to a GMP process.
Method and limits
This article is public-regulation, standard and editorial research, not GMP, data-integrity, validation, legal or compliance audit advice for any company, factory, system or project. It uses no unpublished client data, cases, prices, accuracy or audit results. Official clauses link to the source; scenario layers, priorities and acceptance suggestions are editorial judgement; the specific system boundary, validation scope, applicable regulations and data flows must be confirmed by quality, regulatory, IT and production. Regulations, guidance and platform rules change; the current text, regulatory requirements and contract govern.
Sources
Information is current to 2026-10-28; each public page governs its own scope, version and terms.
- NMPA, Good Manufacturing Practice for Drugs (2010 Revision) (MOH Decree No. 79): State Council Gazette. Production, quality assurance, records and release requirements; official text, not a project compliance conclusion.
- NMPA, Requirements for the Management of Drug Records and Data (Interim) (Announcement No. 74 of 2020): Chongqing Drug Administration reprint. Electronic records, access, audit, backup and validation requirements; the NMPA original governs.
- U.S. FDA, 21 CFR Part 11 — Electronic Records; Electronic Signatures: eCFR. U.S. jurisdictional requirements; not a substitute for Chinese law.
- European Commission, EudraLex Volume 4, Annex 11: Computerised Systems: European Commission PDF. EU GMP reference for computerised systems, validation, audit trails and signatures; applies within the EU scope.
- NIST, AI Risk Management Framework (AI RMF 1.0): NIST PDF. AI risk management, testing and governance reference; voluntary, not a compliance certification.